Proapoptotic targeted peptide — selectively kills fat cell blood vessels (vasculature), causing fat cell death via ischemia
Administration
Subcutaneous injection
Half-life
Short plasma half-life; effects via accumulation in fat vasculature
Most studied use
Experimental obesity treatment — never reached humans due to kidney toxicity concerns
Regulatory status
Not FDA-approved · Never reached human clinical trials · Research compound only · Serious safety concerns halted development
Human evidence
None — no human clinical trials conducted
Preclinical evidence
Strong for fat loss — 39% weight loss in obese primates (4 weeks). Critical: dose-dependent kidney tubular toxicity confirmed in the same primate studies.
EDUCATIONAL TOOL — NOT MEDICAL ADVICE
CRITICAL SAFETY WARNING
Adipotide has documented dose-dependent kidney tubular toxicity in primate studies. No human therapeutic window has been established. Kidney function monitoring (creatinine, BUN, GFR) is non-negotiable for any use. This is the most risk-fraught compound in this guide.
What is Adipotide (FTPP)?
Adipotide (FTPP) is one of the most pharmacologically novel — and most risk-fraught — compounds in the biohacker space. The mechanism is unlike anything else: it's a chimeric peptide with two distinct functional domains. The first domain (CKGGRAKDC) home-targets the peptide to receptors on blood vessels specifically inside white adipose tissue (fat). The second domain (D(KLAKLAK)₂) is a mitochondria-disrupting sequence that kills cells when internalized. Together: the peptide seeks out fat vasculature, binds, enters the vascular endothelial cells, disrupts their mitochondria, kills them — and the fat cells die from loss of blood supply. The fat physically disappears.
The primate results are extraordinary: obese rhesus monkeys treated with Adipotide lost an average of 39% of body weight over 4 weeks. MRI confirmed the fat was gone, not redistributed. Insulin sensitivity improved dramatically. These results generated enormous excitement when published.
The problem — and it is serious — is renal toxicity. The same primate studies documented dose-dependent kidney tubular cell damage: proximal tubular necrosis, elevated creatinine, decreased kidney function. At doses required for dramatic fat loss, meaningful kidney damage occurred. Researchers could not establish a therapeutic window sufficient to justify human clinical trials. Development effectively stopped. The biohacker community uses Adipotide despite these concerns — anyone doing so without kidney function monitoring is taking a risk that cannot be adequately quantified.
How it works
Targeted Fat Vasculature Binding
The CKGGRAKDC domain of Adipotide binds specifically to prohibitin on the surface of endothelial cells lining blood vessels inside white adipose tissue (WAT). Prohibitin is overexpressed on WAT vasculature compared to other tissues — this overexpression creates the targeting selectivity. After binding, the peptide is internalized by the endothelial cells.
Mitochondrial Disruption and Fat Cell Death
Once internalized, the D(KLAKLAK)₂ domain disrupts mitochondrial membranes in the endothelial cells, causing mitochondrial swelling, cytochrome c release, and apoptosis. The vascular endothelial cells of fat tissue die. Fat cells, deprived of blood supply (ischemia), undergo apoptosis and subsequent phagocytosis. The fat physically disappears.
Why the Kidney Gets Hit
Prohibitin is expressed in kidney proximal tubular cells as well as fat vasculature — it is not perfectly selective for fat. At doses required for significant fat loss, Adipotide accumulates in kidneys as well, causing proximal tubular cell death (tubular necrosis). This is the same type of kidney damage seen with nephrotoxic drugs and contrast agents. The renal toxicity is a consequence of imperfect targeting specificity — not a side effect of the killing domain alone.
What the research shows
STUDYScience Translational Medicine · 2011
Adipotide causes dramatic fat loss and renal toxicity in obese primates
Barnhart KF et al.
Obese rhesus monkeys. Adipotide (0.58 mg/kg SC daily, 4 weeks): average 39% body weight reduction, dramatic insulin sensitivity improvement, fat loss confirmed on MRI. Kidney toxicity: reversible tubular damage at effective doses; dose-dependent nephrotoxicity confirmed. The paper that showed both the remarkable efficacy and the kidney toxicity that halted development.
Proapoptotic peptide approach to targeting fat vasculature — mechanism
Kolonin MG et al.
Original paper establishing the prohibitin-targeting approach for fat vasculature elimination. Demonstrated selective targeting and fat reduction in rodent models. Foundational mechanism paper.
✓39% weight loss in obese primates (4 weeks) — documented in Science Translational Medicine
✓Prohibitin-targeting mechanism confirmed — fat vasculature selectivity established
✓Dose-dependent kidney tubular toxicity in primates confirmed
✓Dramatic insulin sensitivity improvement alongside fat loss
?UNCERTAIN
?Effective dose in humans vs. kidney-toxic dose in humans
?Whether a therapeutic window exists in humans
?Long-term recovery from kidney toxicity at effective doses
?Whether lower doses produce meaningful fat loss without nephrotoxicity
What the community reports
—Fat loss: users who have run Adipotide report dramatic, rapid fat reduction — the most dramatic of any compound in the fat-loss space; consistent with the primate data
—Kidney monitoring: the community strongly emphasizes creatinine and kidney function testing before, during, and after any protocol — non-negotiable in any informed community discussion
—Dose controversy: community debate centers on what dose is safe; no established safe human dose exists; users who have run it tend toward very low, infrequent dosing
—The last resort framing: many describe Adipotide as a compound for specific situations — not general weight loss, but targeted stubborn fat after other methods are exhausted
—Significant minority who refuse to use it: a meaningful proportion that has researched Adipotide concludes the kidney risk is unacceptable without an established therapeutic window — this is a rational position
Common misconceptions
"39% weight loss means this is the most effective fat-loss compound."
REALITY
39% fat loss with dose-dependent kidney toxicity is not a viable therapeutic. The efficacy is remarkable; the toxicity at effective doses has no known mitigation. A compound that damages kidneys while burning fat is not a viable option without an established safe dose.
"Lower doses eliminate the kidney risk."
REALITY
The primate data shows dose-dependent nephrotoxicity — lower doses produce less kidney damage. Whether lower doses in humans produce meaningful fat loss without nephrotoxicity is unknown. There is no established human therapeutic window. Lower dose is not the same as established safety.
"The kidney toxicity was reversible in the monkeys."
REALITY
The kidney damage was described as reversible at the doses studied. However: reversible in primates does not equal reversible in humans; without monitoring, users cannot detect damage before it progresses; repeat cycles may produce cumulative damage that is not reversible.
FAT LOSS CONTEXT — ESTABLISHED ALTERNATIVES
Adipotide: most potent fat loss data in any primate, zero human trials, kidney toxicity risk. Semaglutide: ~15% weight loss in humans, established safety profile, GLP-1 class. Tirzepatide: ~22% weight loss in humans, GIP/GLP-1 dual agonist. AOD-9604: targeted lipolysis without kidney toxicity — very different risk profile.
RECONSTITUTION CALCULATOR
EDUCATIONAL TOOL — NOT MEDICAL ADVICE · VERIFY WITH YOUR CLINICIAN
AI COACH PREVIEW
I'm considering Adipotide. What kidney monitoring do I absolutely need?
If you're going to use Adipotide, kidney monitoring isn't optional — it's the only safety mechanism you have. There is no antidote and no way to stop kidney damage after it starts other than stopping the compound early. Here's the non-negotiable protocol: Baseline before any use: full kidney function panel — serum creatinine, BUN (blood urea nitrogen), eGFR (estimated glomerular filtration rate), urinalysis with microscopy. Photograph or document these numbers. You need to know your baseline before any compound that has documented nephrotoxicity. Week 2 check (mid-cycle): repeat creatinine and BUN at minimum. If either is elevated above your baseline, stop immediately. Do not complete the cycle. End of cycle: full panel again — creatinine, BUN, eGFR, urinalysis. Before any subsequent cycle: wait minimum 8 weeks AND get full panel confirming return to baseline. Warning signs that should trigger immediate medical evaluation: decreased urine output, flank or back pain, fatigue out of proportion to activity, foamy or dark-colored urine, any creatinine above your baseline. The honest assessment: The 39% primate weight loss is real. The kidney toxicity that prevented human trials is equally real. Anyone using Adipotide is accepting an unquantified kidney risk — because no human therapeutic window has been established. Regular monitoring can detect early damage; it cannot prevent it. If dramatic fat loss with an established human safety profile is the goal, GLP-1 class compounds (semaglutide, tirzepatide) achieve substantial weight loss. The only reason to consider Adipotide over those options is if you specifically need the prohibitin-targeting fat vasculature mechanism and have exhausted other approaches. What's your current kidney function status — have you had a baseline panel done recently?
CONTINUE IN THE APP
Open PepperLedger to track your Adipotide protocol →
Free to join. No credit card. Ask the Coach about kidney monitoring and protocol design once you're in.
Free to join · No credit card · 23-day Pro trial included